超碰97人人爱人人做-超碰97人人操-超碰97人人操人人干-超碰97人人操人人摸-超碰97人人艹-超碰97人人干人人爱

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产视频三级 | 国产一级大片在线观看 | 亚洲成a人v欧美综合天堂 | 久章草在线视频播放国产下载 | 国产午夜在线免费 | 国产精品视频一区二区三区 | 国产又粗又猛又大爽视频 | 欧美日韩在线观看免费 | 国产欧美日韩区二区三区 | 中文岛国精品亚洲一区 | 欧美2区 | 国产精品宾馆精品酒店 | 国产乱女乱子视频在线播放 | 九一国产精品视频 | 愛妃)日韩视频在线免费观看 | 99久视频 | 殴美亚洲日韩国产一区三区 | 中文字字幕乱码 | 日韩国产精品欧美一区二区 | 国产1区2区3区4区免费 | 亚洲中文字幕丝袜制服视频 | 好吊色在线观 | 国产一区在线视 | 精品在线观看 | 国产专区第一页在线看 | 欧美激情国产日韩精品一区18 | 欧美精品一区二区三区aⅴ天堂 | 国产视频99kai| 乱码高清在线观看 | 国产免费怡红院视频 | 成人国内免费精品视频在线观看 | 国产视频亚洲 | 一级视频在线播放 | 欧美交a欧美 | 五月天婷婷激情 | 亚洲jizz | 精品国产欧美在线小说区 | 欧美日韩国产亚洲精品 | 日韩午夜成人精品免费网 | 正在播放国产自在线拍 | 亚洲精品911永久在线观看 |